Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Trial Parameters
Brief Summary
Rationale: Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown. Objective: To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.
Eligibility Criteria
Inclusion Criteria: * Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma * Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022 * Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide) * Age ≥ 18 years Exclusion Criteria: * Prior cranial radiotherapy * Contra-indication for MRI imaging * Chemotherapy delivered before radiotherapy * Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3) * Combination photon and proton therapy * Patient has previously opted-out of the use of their data for research